Brief: Monopar Therapeutics Reports Fourth Quarter And Full-Year 2022 Financial Results

Monopar Therapeutics

23/03/2023 11:19

March 23 (Reuters) - Monopar Therapeutics Inc  MNPR.O :
    * MONOPAR THERAPEUTICS REPORTS FOURTH QUARTER AND FULL-YEAR
2022 FINANCIAL RESULTS AND RECENT DEVELOPMENTS
    * CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AS OF
DECEMBER
31, 2022, WERE $13.1 MILLION
    * EXPECTS CURRENT FUNDS WILL BE SUFFICIENT TO OBTAIN TOPLINE
RESULTS FROM ONGOING PHASE 1B CAMSIRUBICIN CLINICAL TRIAL
    * WILL REQUIRE ADDITIONAL FUNDING AND/OR A CORPORATE PARTNER
TO
ADVANCE ITS CLINICAL AND PRECLINICAL PROGRAMS
    * ANTICIPATES IT WILL SEEK TO RAISE ADDITIONAL CAPITAL
AND/OR
ENGAGE A PARTNER WITHIN NEXT 12 MONTHS TO FUND FUTURE OPERATIONS
    * NET LOSS FOR THE FOURTH QUARTER OF 2022 WAS $2.9 MILLION
OR
$0.22 PER SHARE
    * Q4 EARNINGS PER SHARE VIEW $-0.21 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX6FmJfS 
Further company coverage:  MNPR.O 

 ((Reuters.Briefs@thomsonreuters.com;))